{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"The primary end point is the rate of patients achieving an objective response (defined according to the International Myeloma Working Group uniform response criteria), including minimal response, (as derived from the European Society for Blood and Marrow Transplantation criteria), achieved at any time until end of study and confirmed on two consecutive assessments at 4 weeks interval.","groups":[{"description":"0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles","id":"OG000","title":"IPH2101 0.2 mg/kg"},{"description":"2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles","id":"OG001","title":"IPH2101 2 mg/kg"}],"paramType":"NUMBER","populationDescription":"The ITT population included all randomized subjects.","reportingStatus":"POSTED","timeFrame":"from start to end of study (14 months)","title":"Rate of Patients Achieving an Objective Response","type":"PRIMARY","unitOfMeasure":"participants"}